Genetron Health to Participate in the Goldman Sachs Healthcare Corporate Day
Genetron Holdings Limited (Nasdaq: GTH), a leading precision oncology platform in China, announced participation in the virtual Goldman Sachs Healthcare Corporate Day on June 24, 2022. Management, including CEO Sizhen Wang and CFO Evan Xu, will attend investor meetings. Genetron specializes in molecular profiling tests, early cancer screening, and companion diagnostics, leveraging advanced molecular biology and data science technologies. The company offers a comprehensive oncology portfolio addressing cancer management needs and collaborates with global biopharmaceutical firms. For more information, visit Genetron Health's website.
- None.
- None.
BEIJING, June 16, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that management will be participating in the virtual Goldman Sachs Healthcare Corporate Day.
Genetron’s management team, Sizhen Wang, co-founder and Chief Executive Officer and Evan Xu, Chief Financial Officer, will attend investor meetings on Friday, June 24, 2022.
Interested parties may request more information by contacting their sales representative at Goldman Sachs.
About Genetron Holdings Limited
Genetron Holdings Limited (“Genetron Health” or the “Company”) (Nasdaq: GTH) is a leading precision oncology platform company in China that specializes in cancer molecular profiling and harnesses advanced technologies in molecular biology and data science to transform cancer treatment. The Company has developed a comprehensive oncology portfolio that covers the entire spectrum of cancer management, addressing needs and challenges from early screening, diagnosis and treatment recommendations, as well as continuous disease monitoring and care. Genetron Health also partners with global biopharmaceutical companies and offers customized services and products. For more information, please visit https://ir.genetronhealth.com/.
Safe Harbor Statement
This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the Company’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and a number of factors could cause actual results to differ materially from those contained in any forward-looking statement. In some cases, forward-looking statements can be identified by words or phrases such as “may”, “will,” “expect,” “anticipate,” “target,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. Further information regarding these and other risks, uncertainties or factors is included in the Company’s filings with the SEC. All information provided in this press release is as of the date of this press release, and the Company does not undertake any duty to update such information, except as required under applicable law.
Investor Relations Contact
Email: ir@genetronhealth.com
FAQ
What is Genetron Holdings Limited's stock symbol?
When will Genetron Holdings participate in the Goldman Sachs Healthcare Corporate Day?
Who are the key executives attending the investor meetings for Genetron Holdings?
What does Genetron Holdings specialize in?
How can I get more information about Genetron Holdings?
